Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs. The streamlining would save 8 billion Danish krone ($1.25 billion) by the end of 2026, sa...

Redirecting to full article...